European Journal of Cancer
IF
9.16
Papers
37.9k
Papers 10,000
1 page of 1,000 pages (10k results)
Newest
Abstract null null Background null Immune checkpoint inhibitors are widely used in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC). We aimed to describe response rates to taxanes after progression on nivolumab in R/M HNSCC patients. null null null Methods null In this multicentric retrospective comparative study, we included patients treated with taxane monotherapy from 2014 to 2020. Patients were divided into two groups depending on whether they received nivolumab ...
Source
#1Mihaela Aldea (University of Paris)
Last. Francesco RicciH-Index: 8
view all 24 authors...
Source
#1Ulrike KeimH-Index: 15
#2Sara GandiniH-Index: 69
Last. Claus GarbeH-Index: 115
view all 9 authors...
Source
#1Yoshihiko SakataH-Index: 5
#2Shinya Sakata (Kumamoto University)H-Index: 9
Last. Takashi Yokoi (Hyogo College of Medicine)H-Index: 13
view all 22 authors...
Abstract null null Background null Osimertinib is the standard of care in the initial treatment for advanced epidermal growth factor receptor (EGFR) mutation–positive lung cancer. However, clinical data and reliable prognostic biomarkers are insufficient. null null null Methods null We performed a retrospective multicentre cohort study for 538 EGFR mutation–positive patients, who received osimertinib as the initial treatment between August 2018 and December 2019. The main outcome was progression...
Source
#1Carl M. Thielmann (University of Duisburg)
#2Eleftheria Chorti (University of Duisburg)
Last. Inga Möller (University of Duisburg)
view all 29 authors...
Abstract null null Background null NF1-mutated tumours represent a small subset (10–15%) of melanomas, not sufficiently analysed in large clinical cohorts. This study investigated the largest multicentre collection of NF1-mutated melanomas to date. null null null Methods null This study analysed a multicentre tumour tissue sample cohort from 266 patients with NF1-mutated melanoma. Targeted next-generation sequencing of the TERT promoter and 29 relevant melanoma genes was performed. Survival was ...
Source
#1Yu-Jing Liang (Sun Yat-sen University)H-Index: 4
#2Dong-Xiang Wen (Sun Yat-sen University)H-Index: 1
Last. Hai-Qiang Mai (Sun Yat-sen University)H-Index: 16
view all 9 authors...
Abstract null null Purpose null To compare the prognosis and adverse effects of induction or adjuvant chemotherapy (IC or AC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in paediatric nasopharyngeal carcinoma (NPC) patients in the intensity-modulated radiotherapy (IMRT) era. null null null Methods and materials null 549 patients diagnosed from 2005 to 2021 were enrolled. Our primary endpoint was progression-free survival (PFS). The recursive partitioning analysis (RPA) was applied...
Source
#1Ruben Van Paemel (FWO: Research Foundation - Flanders)
#2Charlotte Vandeputte (Ghent University Hospital)
Last. Nadine Van Roy (Ghent University Hospital)H-Index: 46
view all 26 authors...
Background null Paediatric tumours are often characterised by the presence of recurrent DNA copy number alterations (CNAs). These DNA copy number profiles, obtained from a tissue biopsy, can aid in the correct prognostic classification and therapeutic stratification of several paediatric cancer entities (e.g. MYCN amplification in neuroblastoma) and are part of the routine diagnostic practice. Liquid biopsies (LQBs) offer a potentially safer alternative for such invasive tumour tissue biopsies a...
Source
#1Christopher Wills (Cardiff University)
#2Yazhou He (SCU: Sichuan University)
Last. Richard Kaplan (UCL: University College London)H-Index: 61
view all 25 authors...
BACKGROUND While genome-wide association studies (GWAS) have identified germline variants influencing the risk of developing colorectal cancer (CRC), there has been limited examination of the possible role of inherited variation as a determinant of patient outcome. PATIENTS AND METHODS We performed a GWAS for overall survival (OS) in 1926 patients with advanced CRC from the COIN and COIN-B clinical trials. For single nucleotide polymorphisms (SNPs) showing an association with OS (P < 1.0 × 10-5)...
Source
#1Ugo De GiorgiH-Index: 56
#2Maha Hussain (NU: Northwestern University)H-Index: 80
Last. Joyce Steinberg (Astellas Pharma)H-Index: 13
view all 14 authors...
BACKGROUND Enzalutamide combined with androgen deprivation therapy (ADT) significantly prolonged metastasis-free survival and overall survival (OS) versus ADT alone in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) with rapidly rising prostate-specific antigen (PSA). The objective of this post hoc analysis of the PROSPER trial is to evaluate OS benefit and safety of enzalutamide in patients across age and regional subgroups. PATIENTS AND METHODS Eligible men with nmCR...
Source
#1Janine StutterheimH-Index: 6
#2P De Lorenzo (UNIMIB: University of Milano-Bicocca)H-Index: 9
Last. Rob PietersH-Index: 108
view all 27 authors...
Abstract null null Background null The outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior to non-infant ALL patients. Here, we describe the outcome and prognostic factors for 167 infants with KMT2A-germline ALL enrolled in the Interfant-06 study. null null null Methods null Univariate analysis on prognostic factors (age, white blood cell count at diagnosis, prednisolone response and CD10 expres...
Source
12345678910
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.